Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has provided an update.
Oxford Biomedica has announced a £60 million equity raise to fund strategic investments in expanding its global CDMO network, particularly in the US. This expansion is expected to accelerate revenue growth and improve margins, with projected revenues of £220-240 million in FY2026 and 25-30% year-on-year growth in 2027 and 2028. The company aims to enhance its manufacturing capabilities and service offerings to meet growing client demand, positioning itself for stronger profitability and a larger share of the viral vector market.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s score is driven by robust earnings call outlook and strategic corporate events, offsetting financial weaknesses. Technical momentum supports the score, but valuation challenges persist.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica plc is a global cell and gene therapy contract development and manufacturing organization (CDMO) known for its innovation and quality in the industry. The company focuses on viral vector manufacturing and aims to strengthen its market position by expanding its capabilities, particularly in the United States.
Average Trading Volume: 147,657
Technical Sentiment Signal: Hold
Current Market Cap: £470.5M
For an in-depth examination of OXB stock, go to TipRanks’ Overview page.